{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:24:05Z","timestamp":1790900645222,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Small cell lung cancer (SCLC) is highly invasive with poor prognosis, and its treatment has historically been hindered due to the absence of targetable driver genomic alterations. However, the high genomic instability and replication stress in SCLC have made poly(ADP-ribose) polymerases (PARPs) inhibitors a focus of research. Pamiparib is an orally available PARP1\/2 inhibitor with high selectivity, strong PARP trapping activity, and excellent brain penetration. Utilizing pamiparib as consolidation maintenance therapy in limited-stage SCLC holds promise for improving survival outcomes and offering a viable therapeutic approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-arm, open-label phase II trial will enroll patients aged 18\u201375 years with histologically\/cytologically confirmed, limited-stage SCLC who have not progressed following definitive platinum-based cCRT and have an ECOG PS of 0 or 1. Patients will be excluded if they have histologically confirmed mixed SCLC or NSCLC, or have undergone previous tumor resection, or can be treated with surgery or stereotactic body radiation therapy\/stereotactic ablative radiation therapy. Participants will receive pamiparib 40\u00a0mg twice daily every 3 weeks within 2 to 6 weeks after cCRT for up to 1 year or until disease progression according to RECIST v1.1. The primary endpoint is the 1-year progression-free survival (PFS) rate assessed by investigators per RECIST v1.1. Secondary endpoints include PFS, objective response rate, and duration of response assessed by investigators per RECIST 1.1, overall survival, time to distant metastasis, and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The study will provide valuable data on the feasibility, safety, and effectiveness of pamiparib as a consolidation therapy after cCRT in patients with LS-SCLC. The correlation between molecular typing or gene expression profile of the disease and curative response will be further explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT05483543 at clinicaltrials.gov.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-024-02437-2","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T05:01:39Z","timestamp":1712898099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Jiuang","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"3","key":"2437_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","volume":"75","author":"SP Riaz","year":"2012","unstructured":"Riaz SP, L\u00fcchtenborg M, Coupland VH, Spicer J, Peake MD, M\u00f8ller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012;75(3):280\u20134.","journal-title":"Lung Cancer"},{"issue":"1","key":"2437_CR2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, Zhou X, Zhou C, Zhang H, Cheng Z, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339.","journal-title":"Sci Rep"},{"key":"2437_CR3","unstructured":"Small Lung Cell Cancer. (Version 3.2023) [https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf]."},{"issue":"3","key":"2437_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","volume":"9","author":"WJ Petty","year":"2023","unstructured":"Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung Cancer: a review. JAMA Oncol. 2023;9(3):419\u201329.","journal-title":"JAMA Oncol"},{"issue":"15","key":"2437_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/djp200","volume":"101","author":"SM Lee","year":"2009","unstructured":"Lee SM, Woll PJ, Rudd R, Ferry D, O\u2019Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101(15):1049\u201357.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2437_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/JTO.0000000000000343","volume":"10","author":"S Lu","year":"2015","unstructured":"Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2015;10(1):206\u201311.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"12","key":"2437_CR7","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodr\u00edguez-Cid J, Schenker M, et al. Nivolumab and Ipilimumab as maintenance therapy in extensive-disease small-cell Lung Cancer: CheckMate 451. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(12):1349\u201359.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2019.06.011","volume":"134","author":"A Santo","year":"2019","unstructured":"Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, et al. Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: a multicenter, randomized, phase 3 trial. Lung Cancer (Amsterdam Netherlands). 2019;134:121\u20136.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"15","key":"2437_CR9","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","volume":"33","author":"NE Ready","year":"2015","unstructured":"Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung Cancer: a Randomized, Double-Blind, placebo-controlled phase II Study-CALGB 30504 (Alliance). J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(15):1660\u20135.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"6330","key":"2437_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"key":"2437_CR11","doi-asserted-by":"crossref","unstructured":"Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP inhibitors in ovarian Cancer: the Route to Ithaca. Diagnostics (Basel) 2019, 9(2).","DOI":"10.3390\/diagnostics9020055"},{"issue":"1","key":"2437_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","volume":"3","author":"J Murai","year":"2019","unstructured":"Murai J, Pommier Y. PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annual Rev Cancer Biology. 2019;3(1):131\u201350.","journal-title":"Annual Rev Cancer Biology"},{"issue":"9","key":"2437_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","volume":"2","author":"LA Byers","year":"2012","unstructured":"Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798\u2013811.","journal-title":"Cancer Discov"},{"issue":"7","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2437_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110\u201320.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.molcel.2017.06.008","volume":"67","author":"S Sivanand","year":"2017","unstructured":"Sivanand S, Rhoades S, Jiang Q, Lee JV, Benci J, Zhang J, Yuan S, Viney I, Zhao S, Carrer A, et al. Nuclear Acetyl-CoA production by ACLY promotes homologous recombination. Mol Cell. 2017;67(2):252\u2013e265256.","journal-title":"Mol Cell"},{"issue":"6","key":"2437_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.celrep.2015.04.014","volume":"11","author":"KM Aird","year":"2015","unstructured":"Aird KM, Worth AJ, Snyder NW, Lee JV, Sivanand S, Liu Q, Blair IA, Wellen KE, Zhang R. ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep. 2015;11(6):893\u2013901.","journal-title":"Cell Rep"},{"key":"2437_CR18","doi-asserted-by":"crossref","unstructured":"Bian X, Lin W. Targeting DNA replication stress and DNA double-strand break repair for optimizing SCLC Treatment. Cancers (Basel) 2019, 11(9).","DOI":"10.3390\/cancers11091289"},{"issue":"5","key":"2437_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41418-023-01141-0","volume":"30","author":"S Ragu","year":"2023","unstructured":"Ragu S, Droin N, Matos-Rodrigues G, Barascu A, Caillat S, Zarkovic G, Siberchicot C, Dardillac E, Gelot C, Guirouilh-Barbat J, et al. A noncanonical response to replication stress protects genome stability through ROS production, in an adaptive manner. Cell Death Differ. 2023;30(5):1349\u201365.","journal-title":"Cell Death Differ"},{"issue":"3","key":"2437_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41418-019-0403-9","volume":"27","author":"R Vanzo","year":"2020","unstructured":"Vanzo R, Bartkova J, Merchut-Maya JM, Hall A, Bouchal J, Dyrskj\u00f8t L, Frankel LB, Gorgoulis V, Maya-Mendoza A, J\u00e4\u00e4ttel\u00e4 M, et al. Autophagy role(s) in response to oncogenes and DNA replication stress. Cell Death Differ. 2020;27(3):1134\u201353.","journal-title":"Cell Death Differ"},{"key":"2437_CR21","doi-asserted-by":"crossref","unstructured":"Fournier LA, Kumar A, Stirling PC. Chromatin as a platform for modulating the replication stress response. Genes (Basel) 2018, 9(12).","DOI":"10.3390\/genes9120622"},{"issue":"6","key":"2437_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1349-7006.2012.02268.x","volume":"103","author":"T Hirai","year":"2012","unstructured":"Hirai T, Shirai H, Fujimori H, Okayasu R, Sasai K, Masutani M. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation. Cancer Sci. 2012;103(6):1045\u201350.","journal-title":"Cancer Sci"},{"key":"2437_CR23","doi-asserted-by":"crossref","unstructured":"C\u00e9saire M, Thariat J, Cand\u00e9ias SM, Stefan D, Saintigny Y, Chevalier F. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci 2018, 19(12).","DOI":"10.3390\/ijms19123793"},{"issue":"24","key":"2437_CR24","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","volume":"63","author":"H Wang","year":"2020","unstructured":"Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, Luo L, Kuang X, Qiu M, Lv L, et al. Discovery of Pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in Clinical Development. J Med Chem. 2020;63(24):15541\u201363.","journal-title":"J Med Chem"},{"issue":"9","key":"2437_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020;22(9):431\u201340.","journal-title":"Neoplasia"},{"issue":"11","key":"2437_CR26","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Pamiparib: first approval. Drugs. 2021;81(11):1343\u20138.","journal-title":"Drugs"},{"issue":"3","key":"2437_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-022-06785-z","volume":"197","author":"B Xu","year":"2023","unstructured":"Xu B, Sun T, Shi Y, Cui J, Yin Y, Ouyang Q, Liu Q, Zhang Q, Chen Y, Wang S, et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast Cancer Res Treat. 2023;197(3):489\u2013501.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2437_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","volume":"28","author":"X Wu","year":"2022","unstructured":"Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H, et al. Pamiparib Monotherapy for patients with germline BRCA1\/2-Mutated ovarian Cancer previously treated with at Least Two Lines of Chemotherapy: a Multicenter, Open-Label, phase II study. Clin Cancer Research: Official J Am Association Cancer Res. 2022;28(4):653\u201361.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"4","key":"2437_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41416-021-01632-2","volume":"126","author":"JD Lickliter","year":"2022","unstructured":"Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A\/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer. 2022;126(4):576\u201385.","journal-title":"Br J Cancer"},{"issue":"9","key":"2437_CR30","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","volume":"20","author":"M Friedlander","year":"2019","unstructured":"Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol. 2019;20(9):1306\u201315.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2437_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Pujol JL, Dafni U, D\u00f3mine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial. Annals Oncology: Official J Eur Soc Med Oncol. 2022;33(1):67\u201379.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"3","key":"2437_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","volume":"22","author":"BH Gr\u00f8nberg","year":"2021","unstructured":"Gr\u00f8nberg BH, Killingberg KT, Fl\u00f8tten \u00d8, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(3):321\u201331.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2437_CR33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116\u201325.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2437_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","volume":"7","author":"J de Bono","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, et al. Phase I, Dose-Escalation, two-part trial of the PARP inhibitor Talazoparib in patients with Advanced Germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7(6):620\u20139.","journal-title":"Cancer Discov"},{"issue":"8","key":"2437_CR35","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","volume":"16","author":"X Ai","year":"2021","unstructured":"Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, Zhang X, Dong X, He J, Li X, et al. Efficacy and safety of Niraparib as maintenance treatment in patients with extensive-stage SCLC after First-Line chemotherapy: a Randomized, Double-Blind, phase 3 study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(8):1403\u201314.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"8","key":"2437_CR36","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","volume":"14","author":"A Thomas","year":"2019","unstructured":"Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, et al. Durvalumab in Combination with Olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(8):1447\u201357.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"2437_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2022.07.007","volume":"171","author":"P Woll","year":"2022","unstructured":"Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, Shah R, Bhosle J, Hodgkinson E, Watkins B, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer (Amsterdam Netherlands). 2022;171:26\u201333.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"11","key":"2437_CR38","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","volume":"72","author":"S Ying","year":"2012","unstructured":"Ying S, Hamdy FC, Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res. 2012;72(11):2814\u201321.","journal-title":"Cancer Res"},{"issue":"3","key":"2437_CR39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1535-7163.MCT-05-0418","volume":"5","author":"G No\u00ebl","year":"2006","unstructured":"No\u00ebl G, Godon C, Fernet M, Giocanti N, M\u00e9gnin-Chanet F, Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther. 2006;5(3):564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"2437_CR40","doi-asserted-by":"publisher","first-page":"101885","DOI":"10.1016\/j.redox.2021.101885","volume":"41","author":"JM Mart\u00ed","year":"2021","unstructured":"Mart\u00ed JM, Garcia-Diaz A, Delgado-Bellido D, O\u2019Valle F, Gonz\u00e1lez-Flores A, Carlevaris O, Rodr\u00edguez-Vargas JM, Am\u00e9 JC, Dantzer F, King GL, et al. Selective modulation by PARP-1 of HIF-1\u03b1-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions. Redox Biol. 2021;41:101885.","journal-title":"Redox Biol"},{"key":"2437_CR41","doi-asserted-by":"publisher","first-page":"215919","DOI":"10.1016\/j.canlet.2022.215919","volume":"550","author":"D Shen","year":"2022","unstructured":"Shen D, Luo J, Chen L, Ma W, Mao X, Zhang Y, Zheng J, Wang Y, Wan J, Wang S, et al. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Cancer Lett. 2022;550:215919.","journal-title":"Cancer Lett"},{"key":"2437_CR42","doi-asserted-by":"crossref","unstructured":"Haase S, Banerjee K, Mujeeb AA, Hartlage CS, N\u00fa\u00f1ez FM, N\u00fa\u00f1ez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi MN et al. H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models. J Clin Invest 2022, 132(22).","DOI":"10.1172\/JCI154229"},{"issue":"1","key":"2437_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13014-017-0788-x","volume":"12","author":"J Zhang","year":"2017","unstructured":"Zhang J, Fan M, Liu D, Zhao K-L, Wu K-L, Zhao W-X, Zhu Z-F, Fu X-L. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Radiat Oncol. 2017;12(1):51.","journal-title":"Radiat Oncol"},{"key":"2437_CR44","doi-asserted-by":"publisher","first-page":"833478","DOI":"10.3389\/fonc.2022.833478","volume":"12","author":"C Qi","year":"2022","unstructured":"Qi C, Li W, Li H, Wen F, Zhou L, Sun X, Yu H. Benefits of prophylactic cranial irradiation in the MRI era for patients with Limited Stage Small Cell Lung Cancer. Front Oncol. 2022;12:833478.","journal-title":"Front Oncol"},{"issue":"6","key":"2437_CR45","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/j.prro.2019.06.014","volume":"9","author":"MK Farris","year":"2019","unstructured":"Farris MK, Wheless WH, Hughes RT, Soike MH, Masters AH, Helis CA, Chan MD, Cramer CK, Ruiz J, Lycan T, et al. Limited-Stage Small Cell Lung Cancer: is prophylactic cranial irradiation necessary? Pract Radiat Oncol. 2019;9(6):e599\u2013607.","journal-title":"Pract Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-024-02437-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-024-02437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T05:03:07Z","timestamp":1712898187000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-024-02437-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1186\/s13014-024-02437-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Medical Ethics Committee of Fudan University Shanghai Cancer Center approved this study (LSSCLCPARPI-01). Administrative permissions were obtained to access the data used in this study. All patients signed the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}